1-6 of 6
Frances R. Balkwill
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth

Available to Purchase
Hilary A. Kenny, Carman Ka Man Ip, Lucy Kelliher, Tejas Samantaray, Kasjusz Kordylewicz, Rachael Hoffmann, Sarah Rauch, Beatrice Malacrida, Sophie L.P. Skingsley, Frances R. Balkwill, Chiara Battistini, Ugo Cavallaro, Wolf R. Wiedemeyer, Ernst Lengyel
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther OF1–OF13.
https://doi.org/10.1158/1535-7163.MCT-23-0863
Published: 28 April 2025
View articletitled, Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth
Open the PDF for Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth in another window
Includes: Supplementary data
Journal Articles

Immune Mechanisms of Resistance to Cediranib in Ovarian Cancer

Open Access
Ganga Gopinathan, Chiara Berlato, Anissa Lakhani, Ludmila Szabova, Colin Pegrum, Ana-Rita Pedrosa, Florian Laforets, Eleni Maniati, Frances R. Balkwill
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (6): 1030–1043.
https://doi.org/10.1158/1535-7163.MCT-21-0689
Published: 01 June 2022
View articletitled, Immune Mechanisms of Resistance to Cediranib in Ovarian Cancer
Open the PDF for Immune Mechanisms of Resistance to Cediranib in Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Ovarian cancer cell–derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis

Free
Thorsten Hagemann, Stephen C. Robinson, Richard G. Thompson, Kellie Charles, Hagen Kulbe, Frances R. Balkwill
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (7): 1993–2002.
https://doi.org/10.1158/1535-7163.MCT-07-0118
Published: 09 July 2007
View articletitled, Ovarian cancer cell–derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis
Open the PDF for Ovarian cancer cell–derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis in another window
Journal Articles

Expression and regulation of tumor necrosis factor α in normal and malignant ovarian epithelium

Free
Peter W. Szlosarek, Matthew J. Grimshaw, Hagen Kulbe, Julia L. Wilson, George D. Wilbanks, Frances Burke, Frances R. Balkwill
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2006) 5 (2): 382–390.
https://doi.org/10.1158/1535-7163.MCT-05-0303
Published: 27 February 2006
View articletitled, Expression and regulation of tumor necrosis factor α in normal and malignant ovarian epithelium
Open the PDF for Expression and regulation of tumor necrosis factor α in normal and malignant ovarian epithelium in another window
Journal Articles

An Anti-Tumor Necrosis Factor-α Antibody Inhibits the Development of Experimental Skin Tumors

Free
Kate A. Scott, Robert J. Moore, Caroline H. Arnott, Nick East, Richard G. Thompson, Bernard J. Scallon, David J. Shealy, Frances R. Balkwill
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2003) 2 (5): 445–451.
Published: 01 May 2003
View articletitled, An Anti-Tumor Necrosis Factor-α Antibody Inhibits the Development of Experimental Skin Tumors
Open the PDF for An Anti-Tumor Necrosis Factor-α Antibody Inhibits the Development of Experimental Skin Tumors in another window
Journal Articles

Endothelin-2 Is a Hypoxia-induced Autocrine Survival Factor for Breast Tumor Cells

Free
Matthew J. Grimshaw, Stuart Naylor, Frances R. Balkwill
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2002) 1 (14): 1273–1281.
Published: 01 December 2002
View articletitled, Endothelin-2 Is a Hypoxia-induced Autocrine Survival Factor for Breast Tumor Cells
Open the PDF for Endothelin-2 Is a Hypoxia-induced Autocrine Survival Factor for Breast Tumor Cells in another window